Lucid Diagnostics LUCD
Lucid Diagnostics Q1 FY25: revenue $828K, down 17%; diluted EPS −$0.52
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001641172-25-009986
Key figures from this report
These are the numbers Lucid Diagnostics reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$828K−17% from $1.0M in Q1 FY2410-Q income statement, on EDGAR
- Net income−$26.9MAgainst −$10.6M in Q1 FY2410-Q income statement, on EDGAR
- Diluted EPS−$0.52Against −$0.40 in Q1 FY2410-Q income statement, on EDGAR
- Cash and cash equivalents$25.2M+2% from $24.8M in Q1 FY2410-Q balance sheet, on EDGAR
- Cash from operations−$12.5MAgainst −$12.6M in Q1 FY2410-Q cash flow statement, on EDGAR
